

Stallergenes Greer plc (STAGR) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/SC4206B025FEN.html>

Date: January 2020

Pages: 41

Price: US\$ 125.00 (Single User License)

ID: SC4206B025FEN

Abstracts

Stallergenes Greer plc (STAGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Stallergenes Greer plc (Stallergenes Greer), formerly Ares Allergy Holdings plc is a biopharmaceutical company, which provides treatments for allergy-related respiratory diseases. The company develops diagnostic tests and products with principal focus on allergies. The company offers treatment for important respiratory diseases, which include severe rhino conjunctivitis and rhinitis, and allergic asthma. Stallergenes Greer provides allergen immunotherapy in various dosage forms including injectable or subcutaneous injections, liquid sublinguals and solid sublinguals. Its research and development activities involve development of candidate products, laboratory research, clinical development and regulatory activities. The company distributes its products to various countries in North America, Europe, Africa; Asia and in Australia. Stallergenes Greer is headquartered in London, the UK.

Stallergenes Greer plc Key Recent Developments

Oct 17,2019: Stallergenes Greer and Anergis initiate new study to predict efficacy of second-generation allergen immunotherapy

Apr 17,2019: Stallergenes Greer reports continued sales growth in the first quarter 2019

Mar 21,2019: Stallergenes Greer delivers 2018 sales and EBITDA in line with recent

outlook

Feb 13,2019: Stallergenes Greer delivers 2018 sales in line with outlook

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Stallergenes Greer plc - Key Facts
Stallergenes Greer plc - Key Employees
Stallergenes Greer plc - Key Employee Biographies
Stallergenes Greer plc - Major Products and Services
Stallergenes Greer plc - History
Stallergenes Greer plc - Company Statement
Stallergenes Greer plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Stallergenes Greer plc - Business Description
Product Category: Other
Overview
Performance
Product Category: Subcutaneous
Overview
Performance
Product Category: Sublingual
Overview
Performance
Product Category: Veterinary
Overview
Performance
Geographical Segment: International
Performance
Geographical Segment: Northern and Central Europe
Performance
Geographical Segment: Southern Europe
Performance
Geographical Segment: The US
Performance
R&D Overview

Stallergenes Greer plc - SWOT Analysis
SWOT Analysis - Overview
Stallergenes Greer plc - Strengths
Stallergenes Greer plc - Weaknesses
Stallergenes Greer plc - Opportunities
Stallergenes Greer plc - Threats
Stallergenes Greer plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Stallergenes Greer plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Stallergenes Greer plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Stallergenes Greer plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 17, 2019: Stallergenes Greer and Anergis initiate new study to predict efficacy of second-generation allergen immunotherapy
Apr 17, 2019: Stallergenes Greer reports continued sales growth in the first quarter 2019
Mar 21, 2019: Stallergenes Greer delivers 2018 sales and EBITDA in line with recent outlook
Feb 13, 2019: Stallergenes Greer delivers 2018 sales in line with outlook

SECTION 6 – APPENDIX

Methodology
Ratio Definitions

[About GlobalData](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Stallergenes Greer plc, Key Facts
Stallergenes Greer plc, Key Employees
Stallergenes Greer plc, Key Employee Biographies
Stallergenes Greer plc, Major Products and Services
Stallergenes Greer plc, History
Stallergenes Greer plc, Subsidiaries
Stallergenes Greer plc, Key Competitors
Stallergenes Greer plc, Ratios based on current share price
Stallergenes Greer plc, Annual Ratios
Stallergenes Greer plc, Annual Ratios (Cont...1)
Stallergenes Greer plc, Interim Ratios
Stallergenes Greer plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Stallergenes Greer plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Stallergenes Greer plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Stallergenes Greer plc, Performance Chart (2014 - 2018)

Stallergenes Greer plc, Ratio Charts

Stallergenes Greer plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Stallergenes Greer plc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Sanofi

Perrigo Co Plc

UCB SA

Meda Pharmaceuticals Inc

GlaxoSmithKline Plc

Merck KGaA

I would like to order

Product name: Stallergenes Greer plc (STAGR) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/SC4206B025FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SC4206B025FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970